Tech Company Financing Transactions
Revolution Medicines Funding Round
Third Rock Ventures and private investors participated in a $45 million Series A funding round for Revolution Medicines. The funding round was announced on 2/5/2015.
Transaction Overview
Company Name
Announced On
2/5/2015
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
Third Rock Ventures (Lead Investor)
Proceeds Purpose
With this major advance in chemical synthesis, we now have the opportunity to unlock the full medical benefits of natural products that have been selected through a billion years of evolutionary pressure.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Saginaw Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Revolution Medicines (Nasdaq: RVMD) discovers and develops important new medicines for cancer patients by translating frontier oncology targets--proteins that drive the growth of cancers or that control immune responses that can defeat them.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Goldsmith
Chief Operating Officer
Margaret Horn
Vice President
Adrian Gill
Vice President
Richard Hansen
Vice President
Walter Reiher
Vice President
Jan Smith
Vice President
Xiaolin Wang
VP - Finance
Jack Anders
VP - Human Resources
Luan Wilfong
VP - R & D
Steve Kelsey
Browse more venture capital transactions:
Prev: 2/4/2015: Pulsate venture capital transaction
Next: 2/5/2015: PicsArt venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs